Biotech company Biogen lowered its full-year profit forecast, citing higher costs related to its purchase of drug maker Reata Pharmaceuticals as well as the launch of its Alzheimer's drug.
BBTW editor Peter Green spoke with Beyond Investing co-founder Claire Smith about how her ETF has consistently outperformed the S&P 500, by as much as 30%.
